Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia (Q43564785)

24 November 2017

title

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia (English)

1 reference

24 November 2017

0 references

1 reference

Knapp HH

1

1 reference

24 November 2017

Schrott H

2

1 reference

24 November 2017

Ma P

3

1 reference

24 November 2017

Knopp R

4

1 reference

24 November 2017

Chin B

5

1 reference

24 November 2017

Gaziano JM

6

1 reference

24 November 2017

Donovan JM

7

1 reference

24 November 2017

Burke SK

8

1 reference

24 November 2017

Davidson MH

9

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

American Journal of Medicine

24 November 2017

published in

1 reference

24 November 2017

volume

110

1 reference

24 November 2017

issue

5

1 reference

24 November 2017

page(s)

352-360

1 reference

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Range of serum cholesterol values in the population developing coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Drug treatment of lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Role of the enterohepatic circulation of bile salts in lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

10.1016/S0002-9343(01)00638-6

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference